179 related articles for article (PubMed ID: 28893282)
1. Development of targeted adjuvants for HIV-1 vaccines.
Liu J; Ostrowski M
AIDS Res Ther; 2017 Sep; 14(1):43. PubMed ID: 28893282
[TBL] [Abstract][Full Text] [Related]
2. Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines.
Liu J; Ostrowski M
Hum Vaccin; 2010 Apr; 6(4):355-9. PubMed ID: 20372075
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory combinations: designing the next generation of vaccine adjuvants.
Kornbluth RS; Stone GW
J Leukoc Biol; 2006 Nov; 80(5):1084-102. PubMed ID: 16931603
[TBL] [Abstract][Full Text] [Related]
4. Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.
Rhee EG; Barouch DH
Clin Exp Immunol; 2009 Aug; 157(2):174-80. PubMed ID: 19604256
[TBL] [Abstract][Full Text] [Related]
5. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
6. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS
J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533
[TBL] [Abstract][Full Text] [Related]
7. HIV/AIDS vaccines: 2007.
Robinson HL
Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
[TBL] [Abstract][Full Text] [Related]
8. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
9. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
[TBL] [Abstract][Full Text] [Related]
10. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
Jackson RJ; Worley M; Trivedi S; Ranasinghe C
Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
12. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.
Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745
[TBL] [Abstract][Full Text] [Related]
13. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
Cagigi A; Nilsson A; De Milito A; Chiodi F
Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
[TBL] [Abstract][Full Text] [Related]
14. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 immunogen (remune).
Newsline People AIDS Coalit N Y; 1998 Dec; ():36. PubMed ID: 11367099
[TBL] [Abstract][Full Text] [Related]
16. T cell immune responses to HIV-1.
Vasan S; Schlesinger SJ; Arrode G
Front Biosci; 2007 Jan; 12():2330-43. PubMed ID: 17127243
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor agonists as adjuvants for HIV vaccines.
Stevceva L
Curr Med Chem; 2011; 18(33):5079-82. PubMed ID: 22050755
[TBL] [Abstract][Full Text] [Related]
18. Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines.
Steers NJ; Peachman KK; McClain S; Alving CR; Rao M
Vaccine; 2009 Nov; 27(49):6939-49. PubMed ID: 19748578
[TBL] [Abstract][Full Text] [Related]
19. Prospects for an HIV vaccine: conventional approaches and DNA immunization.
Baumeister MA; Chattergoon MA; Weiner DB
Biotechnol Genet Eng Rev; 2002; 19():205-42. PubMed ID: 12520879
[No Abstract] [Full Text] [Related]
20. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
